Search company, investor...



Series A | Alive

Total Raised


Last Raised

$1.03M | 5 yrs ago

About Otomagnetics

Otomagnetics, a University of Maryland College Park spin-out, is developing a non-invasive method to effectively deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin. The inner ear is behind the blood-labyrinth barrier – vessels that supply blood to the inner ear have walls that are impermeable to most drug molecules, and thus it is a challenge to deliver therapy to treat inner ear diseases. In animal models, Otomagnetics' proprietary magnetic injection system has demonstrated drug delivery to the inner ear. It has also shown improved dosing and therapeutic effect in preclinical models of tinnitus and noise-induced hearing loss, and prevented hearing loss due to chemotherapy regimens.

Headquarters Location

12156-B Parklawn Drive

Rockville, Maryland, 20852,

United States


Missing: Otomagnetics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Otomagnetics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Otomagnetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Otomagnetics is included in 4 Expert Collections, including Medical Devices.


Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health IT

7,901 items

Otomagnetics Patents

Otomagnetics has filed 4 patents.

The 3 most popular patent topics include:

  • Amines
  • Biotechnology
  • Diketones
patents chart

Application Date

Grant Date


Related Topics




Magnetic ordering, Drug delivery devices, Dosage forms, Monoclonal antibodies, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Magnetic ordering, Drug delivery devices, Dosage forms, Monoclonal antibodies, Experimental cancer drugs



Latest Otomagnetics News

Under CEO Abhita Batra, Leading Biotech Startup Otomagnetics, Inc. is Experiencing Exponential Growth

Aug 7, 2020

In the midst of widespread economic and social disruption this cutting edge company has been praised by expert analysts. WASHINGTON, DC, UNITED STATES, August 6, 2020 / / — Cutting edge biotechnology startup, Otomagnetics Inc. has investors and financial analysts buzzing due to its innovative technology which provides effective, non-invasive magnetic drug delivery solutions that have the potential to effectively improve millions of patients´ lives. From an early age, Abhita Batra (CEO of Otomagnetics) was actively and consistently exposed to the inner workings of business, entrepreneurship and the unfathomable potential held by successful biotechnological endeavors; As a youth, Abhita envisioned a vivid journey into the future of human healthcare that promises substantial, measurable and scalable benefits. Immediately after joining Otomagnetics as its Chief Executive Officer the immense potential and substantial responsibility that comes with unbridled innovation was clear; Amongst savvy venture capitalists, investment bankers and seasoned investors, the company has become a hot topic. The young and successful scientist and business leader holds a Global MBA from UCLA and a Masters in Biotechnology with specialization in Pharmaceutical Sciences from University of Pennsylvania; Batra is also a distinguished member of the Forbes Business Councils. The cutting-edge technology championed by Otomagnetics, Inc was successfully developed at the University of Maryland out of the Fischell Department of BIoengineering (BioE) and Institute for Systems Research (ISR) in 2013 – has the potential to dramatically effect the vector of global healthcare. Perhaps one of its most impactful applications is the unrivaled potential this technology holds to dramatically improve the lives of cancer survivors – especially children. With advancements in cancer treatment, more children survive their battle with childhood cancers. Loss of hair, nausea, and vomiting are well known secondary effects. Hearing loss is a less known secondary effect with the potential to disrupt the quality of life for 80% of children after treatment. If a delivery platform such as the one developed by the burgeoning biotech startup could be used to deliver medication that would protect the inner and middle ear from damage, across the blood barrier in a non-invasive way, it could prevent hearing loss in thousands of children. Under Abhita Batra´s efficient leadership, Otomagnetics has successfully raised several million dollars in seed capital and secured a myriad of strategic commercial and development partnerships. In 2017, Otomagnetics was awarded a $2.3 million Fast Track NIH/NCI SBIR Contract to develop a pediatric cancer drug delivery system to prevent hearing loss from chemotherapy regimens. “We are honored and excited to be working closely with the National Institutes of Health to address a pressing clinical need,” said Otomagnetics President and Co-Founder Benjamin Shapiro. “There should not have to be a choice between effective chemo and lifelong hearing loss. Our technology has the potential to allow treatment by chemotherapy without the attendant risk of hearing loss.” Earlier this year Otomagnetics also received additional investment through AngelMD’s Catalyst Fund. They received a Montgomery County Small Business Innovation Research (SBIR) Phase I Matching Grant in September. What excites investors and clinicians alike is the potential to eliminate hearing loss for children undergoing chemotherapy and solve for an unmet clinical need. As the modern world continues to search for more effective solutions across every major industry, companies like Otomagnetics have effectively positioned themselves at the forefront of an irreversible global healthcare revolution. TEA Strategic Media

Otomagnetics Frequently Asked Questions (FAQ)

  • Where is Otomagnetics's headquarters?

    Otomagnetics's headquarters is located at 12156-B Parklawn Drive, Rockville.

  • What is Otomagnetics's latest funding round?

    Otomagnetics's latest funding round is Series A.

  • How much did Otomagnetics raise?

    Otomagnetics raised a total of $1.39M.

  • Who are the investors of Otomagnetics?

    Investors of Otomagnetics include AngelMD, The Maryland Technology Development Corporation and University System of Maryland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.